公开(公告)号：WO1996019989A1

公开(公告)日：1996-07-04

申请号：PCT/US1995016485

申请日：1995-12-20

Applicant: BAYER CORPORATION

Inventor： BAYER CORPORATION ,  JONES, Randy, David

IPC: A61K31/41

CPC classification number: A61K31/433

Abstract: The present invention encompasses a human or veterinary pharmaceutical composition containing a pharmaceutically safe and effective amount of thiadone and the use thereof in treating central nervous system tumor types that are caused by sensitivity to glutathione or other antioxidant adjuvant therapeutic strategies, especially in recurrent malignant tumor types, and resistant due to high levels of aberrant antioxidant tumor enzymes not typically present in normal brain tissue.

Abstract translation: 本发明包括含有药学上安全有效量的thiadone的人或兽用药物组合物及其在治疗由对谷胱甘肽或其它抗氧化剂辅助治疗策略的敏感性引起的中枢神经系统肿瘤类型的用途，特别是在复发性恶性肿瘤类型中 ，并且由于通常不存在于正常脑组织中的高水平的异常抗氧化剂肿瘤酶而具有抗性。

公开(公告)号：WO1998029360A1

公开(公告)日：1998-07-09

申请号：PCT/US1997023114

申请日：1997-12-11

Applicant: BAYER CORPORATION

Inventor： BAYER CORPORATION ,  MARKUSCH, Peter, H.

IPC: C05G03/00

CPC classification number: C08G18/4238 ,  C05G3/0029

Abstract: This invention relates to a process for the preparation of polyurethane encapsulated fertilizer particles. This process comprises applying an isocyanate-reactive component to fertilizer particles, and applying an aliphatic polyisocyanate to fertilizer particles in separate steps to form polyurethane encapsulated fertilizer particles. The two reactants may be applied in either order, with the polyisocyanate being first or last. These two steps may optionally be repeated as many times as necessary to yield polyurethane encapsulated fertilizer particles which contain from 0.5 to 15 % by weight of polyurethane, based on the total weight of the encapsulated fertilizer particles. It is also possible to mix the isocyanate-reactive component and the polyisocyanate together to form a mixture which is then applied to the fertilizer particles. These polyurethane coatings which encapsulate the fertilizer particles are biodegradable.

Abstract translation: 本发明涉及一种制备聚氨酯包封肥料颗粒的方法。 该方法包括将异氰酸酯反应性组分施用于肥料颗粒，以及在分开的步骤中将脂肪族多异氰酸酯施用于肥料颗粒以形成聚氨酯包封的肥料颗粒。 两种反应物可以以任何顺序施加，多异氰酸酯是第一或最后一种。 这两个步骤可以任选地根据需要重复多次以产生基于包封的肥料颗粒的总重量含有0.5至15重量％的聚氨酯的聚氨酯包封的肥料颗粒。 也可以将异氰酸酯反应性组分和多异氰酸酯混合在一起形成混合物，然后将其施加到肥料颗粒上。 这些封装肥料颗粒的聚氨酯涂层是可生物降解的。

公开(公告)号：WO1998022436A1

公开(公告)日：1998-05-28

申请号：PCT/US1997019960

申请日：1997-10-30

Applicant: BAYER CORPORATION

Inventor： BAYER CORPORATION ,  KLUENDER, Harold, C., E. ,  BJORGE, Susan, M. ,  ZADJURA, Lisa, Marie ,  BRUBAKER, William, Frederick

IPC: C07C323/56

CPC classification number: C07D209/48 ,  C07C59/56 ,  C07C59/64 ,  C07C59/66 ,  C07C235/42 ,  C07C235/84 ,  C07C323/56 ,  C07C323/61 ,  C07C323/62 ,  C07C2601/08

Abstract: Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have generalized formula (I) in which T is a pharmaceutically acceptable substituent group; A is CH2, CH, or N; G is CH2 or CH; and R is any of a variety of disclosed substituent groups. The class of compounds of the invention includes ring-containing materials in which the units A and G are joined. The compounds of the invention are mixtures of diastereomers, or individual diastereomers making up these mixtures.

Abstract translation: 用于基质金属蛋白酶的抑制剂，含有它们的药物组合物，以及用于治疗各种生理条件的方法。 本发明化合物具有通式（I），其中T是药学上可接受的取代基; A是CH 2，CH或N; G是CH 2或CH; 并且R 1是各种公开的取代基中的任何一种。 本发明的化合物类包括其中单元A和G连接的含环材料。 本发明的化合物是组成这些混合物的非对映异构体或单独的非对映异构体的混合物。

公开(公告)号：WO1998006427A2

公开(公告)日：1998-02-19

申请号：PCT/US1997014840

申请日：1997-08-05

Applicant: BAYER CORPORATION

Inventor： BAYER CORPORATION ,  MACEK, Joseph ,  BROWN, Karen, K. ,  MOORE, Bobby, O.

IPC: A61K39/00

CPC classification number: A61K39/27 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/552 ,  C12N2710/16734

Abstract: Disclosed herein is an EHV-1 vaccine which provides protection against diseases associated with EHV-1 and EHV-4, and methods of preparing and using the same.

Abstract translation: 本文公开了提供对与EHV-1和EHV-4相关的疾病的保护的EHV-1疫苗及其制备和使用方法。

公开(公告)号：WO1998003654A2

公开(公告)日：1998-01-29

申请号：PCT/US1997011909

申请日：1997-07-09

Applicant: BAYER CORPORATION

Inventor： BAYER CORPORATION ,  GREVE, Jeffrey ,  SHANAFELT, Armen, B. ,  ROCZNIAK, Steven

IPC: C12N15/24

CPC classification number: G01N33/6869 ,  A61K38/00 ,  C07K14/5406 ,  C07K14/7155 ,  G01N33/54306

Abstract: A recombinant human IL-4 mutein numbered in accordance with wild-type IL-4 wherein the mutein comprises at least one amino acid substitution in the binding surface of either the A- or C-alpha helices of the wild-type IL-4 whereby the mutein binds to the IL-4R alpha receptor with at least greater affinity than native IL-4. The substitution is more preferably selected from the group of positions consisting of, in the A-helix, positions 13 and 16, and in the C-helix, positions 81 and 89. A most preferred embodiment is the recombinant human IL-4 mutein wherein the substitution at position 13 is Thr to Asp. Pharmaceutical compositions, amino acid and polynucleotide sequences encoding the muteins, transformed host cells, antibodies to the muteins, and methods of treatment are also described.

Abstract translation: 根据野生型IL-4编号的重组人IL-4突变蛋白，其中所述突变蛋白包含在野生型IL-4的A或C-α螺旋的结合表面中的至少一个氨基酸取代，由此 突变蛋白以比天然IL-4更高的亲和力结合IL-4Rα受体。 该取代更优选选自由A-螺旋中的第13位和第16位以及C-螺旋81和89组成的位置。最优选的实施方案是重组人IL-4突变蛋白，其中 位置13的取代是Thr至Asp。 还描述了编码突变蛋白，转化的宿主细胞，突变蛋白的抗体和治疗方法的药物组合物，氨基酸和多核苷酸序列。

公开(公告)号：WO1998001372A1

公开(公告)日：1998-01-15

申请号：PCT/US1997011975

申请日：1997-07-09

Applicant: PATHFINDER SYSTEMS, INC. ,  BAYER CORPORATION

Inventor： PATHFINDER SYSTEMS, INC. ,  BAYER CORPORATION ,  REINSCH, Frank, G. ,  PARK, Kevin, Kwanghyon

IPC: B65D88/30

CPC classification number: B65G53/60 ,  B65D88/30 ,  B65G53/10

Abstract: The present invention is a device (1) and method for the transportation and metering of precise amounts of particulate matter. The device (1) provides an environmentally and operator safe means of transporting and dispensing precise amounts of particulate matter from the point of manufacture directly to the ultimate consumer of the product. Because of the unique design, the device (1) is readily transportable via standard means of transportation and may be operated by a single individual with no environmental or operator risk. The device (1) further contains, as an integral part thereof, means (27) for the precision metering of the particulate matter being transported. The device may be utilized to store the particulate matter for extended periods of time and, upon being emptied, may be refilled and reused.

Abstract translation: 本发明是用于运输和计量精确量的颗粒物质的装置（1）和方法。 设备（1）提供了一种环境和操作者安全的手段，将精确量的颗粒物质从制造点直接输送到产品的最终消费者。 由于独特的设计，设备（1）可以通过标准的交通工具方便地运输，并且可以由没有环境或操作者风险的单个人操作。 装置（1）作为其整体部分还包含用于精细计量正在运输的颗粒物质的装置（27）。 该装置可以用于在长时间内存储颗粒物质，并且在被清空时可以重新填充和重新使用。

公开(公告)号：WO1997046681A2

公开(公告)日：1997-12-11

申请号：PCT/US1997009787

申请日：1997-06-05

Applicant: BAYER CORPORATION

Inventor： BAYER CORPORATION ,  BLOOMQUIST, Brian, T. ,  McCALEB, Michael, L. ,  CORNFIELD, Linda, J. ,  HEEJA, Yoo-Warren

IPC: C12N15/12

CPC classification number: C07K14/72 ,  A61K38/00

Abstract: The present invention provides a novel galanin receptor protein, the GalR2 receptor. Also provided are the nucleic acid sequences encoding this novel receptor protein as well as methods for using this protein and its nucleic acid sequence, and methods useful for developing and identifying compounds for the treatment of diseases and disorders in which galanin is implicated. The importance of this discovery is manifested in the effects of galanin, which include antinociceptive activity, smooth muscle contraction, cardiovascular activity, pituitary hormone release, cognition, and increased food intake. Thus, this receptor protein is useful for screening for galanin agonist and antagonist activity for controlling these conditions.

Abstract translation: 本发明提供了一种新的甘丙肽受体蛋白GalR2受体。 还提供了编码该新型受体蛋白质的核酸序列以及使用该蛋白质及其核酸序列的方法，以及可用于开发和鉴定用于治疗甘丙肽涉及的疾病和病症的化合物的方法。 这种发现的重要性体现在甘丙肽的作用，其包括抗伤害感受活性，平滑肌收缩，心血管活动，垂体激素释放，认知和增加的食物摄入。 因此，该受体蛋白质可用于筛选用于控制这些病症的甘丙肽激动剂和拮抗剂活性。

公开(公告)号：WO1997046678A1

公开(公告)日：1997-12-11

申请号：PCT/US1997009272

申请日：1997-06-03

Applicant: BAYER CORPORATION

Inventor： BAYER CORPORATION ,  DAVIS, John, N. ,  CHISHOLM, Jane, C. ,  DRACHE, Bettina

IPC: C12N15/12

CPC classification number: C07K14/4711 ,  A01K2217/05 ,  A61K38/00

Abstract: The present invention relates to a PS1/429 nucleic acid, polypeptide, and derivatives thereof, comprising novel nucleotide and amino acid sequences. The invention also relates to methods of using such nucleic acids, polypeptides, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools. Another aspect of the present invention involves antibodies to PS1/429, regulators of PS1/429 gene expression and activity, and methods of treating Alzheimer's disease. The invention especially relates to an isolated nucleic acid comprising a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence set forth in SEQ ID NO:1, with the proviso that the nucleic acid does not contain all or part of the coding sequence for a polypeptide having 467 amino acids as set forth in SEQ ID NO:4 or SEQ ID NO:8. In addition, the invention includes an isolated nucleic acid comprising a PS1/429 unique nucleotide sequence and comprising nucleotides 206 and 207 as set forth in SEQ ID NO:1.

Abstract translation: 本发明涉及包含新的核苷酸和氨基酸序列的PS1 / 429核酸，多肽及其衍生物。 本发明还涉及使用此类核酸，多肽或其衍生物的方法，例如在治疗学，诊断学和研究工具中。 本发明的另一方面涉及PS1 / 429的抗体，PS1 / 429基因表达和活性的调节剂，以及治疗阿尔茨海默氏病的方法。 本发明特别涉及一种分离的核酸，其包含在严格条件下与SEQ ID NO：1所示的核苷酸序列杂交的核苷酸序列，条件是该核酸不含有全部或部分编码序列 多肽具有如SEQ ID NO：4或SEQ ID NO：8所示的467个氨基酸。 此外，本发明包括分离的核酸，其包含PS1 / 429唯一核苷酸序列，并且包含如SEQ ID NO：1所示的核苷酸206和207。

公开(公告)号：WO1997043240A1

公开(公告)日：1997-11-20

申请号：PCT/US1997008608

申请日：1997-05-12

Applicant: BAYER CORPORATION ,  SCOTT, William, J. ,  POPP, Margaret, A. ,  HARTSOUGH, David, S.

Inventor： BAYER CORPORATION

IPC: C07C59/90

CPC classification number: C07C59/90 ,  C07C45/004 ,  C07C45/46 ,  C07C45/63 ,  C07C49/80 ,  C07C49/84 ,  C07C59/88 ,  C07C69/738

Abstract: The present invention provides pharmaceutical compositions and methods for treating certain conditions comprising administering an amount of a compound or composition of the invention which is effective to inhibit the activity of at least one matrix metalloprotease, resulting in achievement of the desired effect. The compounds of the present invention are of generalized formula (I) where nu is 1, 2, 3 or 4 and Ar represents a substituted aromatic moiety. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from atherosclerotic plate rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.

Abstract translation: 本发明提供用于治疗某些病症的药物组合物和方法，包括给予一定量的有效抑制至少一种基质金属蛋白酶活性的本发明化合物或组合物，从而达到预期的效果。 本发明的化合物具有通式（I），其中nu是1,2,3或4，Ar表示取代的芳族部分。 这些化合物可用于抑制基质金属蛋白酶，因此可用于抗MMP的作用，例如骨关节炎，类风湿性关节炎，脓毒性关节炎，牙周病，角膜溃疡，蛋白尿，动脉瘤性主动脉疾病，疏水性表皮松解症，大疱疹，导致炎症的病症 反应，由MMP活性介导的骨质减少，下颌关节疾病，神经系统脱髓鞘疾病，创伤性关节损伤后的肿瘤转移或退行性软骨损失以及动脉粥样硬化板破裂的冠状动脉血栓形成。 本发明还提供了用于治疗这些病症的药物组合物和方法。

公开(公告)号：WO1997041889A1

公开(公告)日：1997-11-13

申请号：PCT/US1997007514

申请日：1997-04-21

Applicant: BAYER CORPORATION ,  BAYER AKTIENGESELLSCHAFT

Inventor： BAYER CORPORATION ,  BAYER AKTIENGESELLSCHAFT ,  ATHERTON, Rebecca, A. ,  SCHMEER, Norbert ,  HALLSTROM, Jean, A. ,  LANE, Jennifer, K. ,  HENNESSY, Kristina, J.

IPC: A61K39/118

CPC classification number: A61K39/118 ,  A61K39/12 ,  A61K39/23 ,  A61K39/265 ,  A61K2039/521 ,  A61K2039/552 ,  A61K2039/70 ,  C12N2710/16734 ,  C12N2740/10034 ,  C12N2750/14334 ,  C12N2770/16034

Abstract: The present invention relates to feline vaccines comprising inactivated a non reactive Chlamydia psittaci for prevention and treatment of chlamydia diseases in cats.

Abstract translation: 本发明涉及用于预防和治疗猫中衣原体疾病的非活性衣原体衣原体灭活的猫科动物疫苗。